{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:23:43Z","timestamp":1788387823998,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100010086","name":"Foundation of Liaoning Province Education Administration","doi-asserted-by":"publisher","award":["LJ232410159023"],"award-info":[{"award-number":["LJ232410159023"]}],"id":[{"id":"10.13039\/501100010086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD19\u2010directed chimeric antigen receptor (CAR)\u2010T\u2010cell therapy has emerged as a second\u2010line option for relapsed\/refractory large B\u2010cell lymphoma (R\/R LBCL). However, its long\u2010term benefits over standard of care (SOC) remain a matter of debate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta\u2010analysis was performed of three randomized controlled trials (ZUMA\u20107, TRANSFORM, BELINDA) and one real\u2010world comparative study evaluating second\u2010line CAR\u2010T versus standard\u2010of\u2010care chemoimmunotherapy (\u00b1autologous stem cell transplantation) in adults with early R\/R LBCL. Hazard ratios (HRs) and 95% CIs for overall survival (OS), event\u2010free survival (EFS), and progression\u2010free survival (PFS) were pooled. Individual patient data were reconstructed to generate pooled Kaplan\u2010Meier survival curves. Subgroup analyses and long\u2010term safety outcomes were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1199 patients were included. Pooled analyses demonstrated a significant benefit of CAR\u2010T over SOC in OS (HR = 0.75; 95% CI, 0.62\u20130.92), EFS (HR = 0.51; 95% CI, 0.33\u20130.78), and PFS (HR = 0.47; 95% CI, 0.39\u20130.58). Three\u2010year OS and PFS estimates from reconstructed data were 53.59% and 44.08% in the CAR\u2010T group, compared to 41.46% and 17.82% with SOC, respectively. Subgroup analyses confirmed consistent EFS across subgroups, including age, disease subtype, and relapse status. Long\u2010term toxicities indicated more frequent hypogammaglobulinemia with CAR\u2010T cell therapy, with no excess in secondary malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Second\u2010line CAR\u2010T therapy significantly improves long\u2010term survival and disease control in R\/R LBCL, with consistent benefit across subgroups and real\u2010world settings. These findings support early CAR\u2010T use as a standard strategy in high\u2010risk LBCL, while emphasizing the importance of timely delivery and long\u2010term monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70317","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:01:00Z","timestamp":1771351260000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Second\u2010line chimeric antigen receptor T\u2010cell therapy versus standard of care in relapsed or refractory large B\u2010cell lymphoma: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"132","author":[{"given":"Lingrong","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Radiation Therapy The First Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dali","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4030-256X","authenticated-orcid":false,"given":"Wenbin","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201003\u2010769620"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)31366\u20100"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000399"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201002067\u20109"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010021\u201001308\u20108"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285828"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00339\u20104"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18335"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1407001"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201023\u20102967"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201023\u20100568"},{"key":"e_1_2_10_20_1","unstructured":"LeeD KambhampatiS BobilloMSO et\u00a0al.Real\u2010world effectiveness and safety outcomes among key subgroups of second\u2010line axicabtagene ciloleucel (axi\u2010cel) for patients with relapsed\/refractory large B\u2010cell lymphoma;Jun 2025:12\u201015. EHA 2025 Congress Abstract S237."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000907"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4504"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009019"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22\u20102276"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2290832"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231168215"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258\u2010023\u201000817\u20105"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70317","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:33:04Z","timestamp":1780655584000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,15]]}},"alternative-id":["10.1002\/cncr.70317"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70317","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"assertion":[{"value":"2025-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70317"}}